RESMED INC
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Aug 9, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Schedule II – Valuation and Qualifying Accounts and Reserves
| PART II | Item 8 |
|---|
SCHEDULE II
VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
June 30, 2024, 2023 and 2022
(in thousands)
| Balance atBeginningof Period | Charged to costs and expenses | Other(deductions) | Balance atEnd ofPeriod | |
|---|---|---|---|---|
| Applied against asset account | ||||
| Allowance for trade accounts receivable | $23,603 | $9,802 | $(12,273) | $21,132 |
| Applied against asset account | ||||
| Allowance for trade accounts receivable | $23,259 | $5,770 | $(5,426) | $23,603 |
| Applied against asset account | ||||
| Allowance for trade accounts receivable (1) | $32,138 | $2,620 | $(11,499) | $23,259 |
(1)Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, “Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments” (Topic 326), effective July 1, 2021.
See accompanying report of independent registered public accounting firm.
-98-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.